

Xavier Jais

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4361203/publications.pdf>

Version: 2024-02-01

146
papers

16,810
citations

22099

59
h-index

15683

125
g-index

151
all docs

151
docs citations

151
times ranked

9121
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. <i>Circulation</i> , 2010, 122, 156-163.	1.6	1,264
2	Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2005, 111, 3105-3111.	1.6	1,040
3	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.	1.6	860
4	Chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801915.	3.1	607
5	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
6	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700889.	3.1	527
7	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134.	1.2	506
8	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2016, 133, 859-871.	1.6	506
9	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2546-2552.	1.2	498
10	Severe Pulmonary Hypertension during Pregnancy. <i>Anesthesiology</i> , 2005, 102, 1133-1137.	1.3	483
11	Immunosuppressive therapy in lupus and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. <i>Arthritis and Rheumatism</i> , 2008, 58, 521-531.	6.7	321
12	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014, 43, 1691-1697.	3.1	319
13	Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2006, 130, 182-189.	0.4	316
14	Pulmonary Veno-Occlusive Disease. <i>Medicine (United States)</i> , 2008, 87, 220-233.	0.4	295
15	Pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2016, 47, 1518-1534.	3.1	289
16	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	3.1	287
17	Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 130, 2189-2208.	1.6	278
18	Deleterious Effects of β -Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension. <i>Gastroenterology</i> , 2006, 130, 120-126.	0.6	277

#	ARTICLE	IF	CITATIONS
19	Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2006, 27, 589-595.	1.0	272
20	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of <i>BMPR2</i> Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1377-1383.	2.5	269
21	Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying an <i>ACVRL1</i> (<i>ALK1</i>) Mutation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 851-861.	2.5	259
22	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 97.	1.2	226
23	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2012, 40, 881-885.	3.1	221
24	Portopulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 637-643.	2.5	220
25	Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>European Heart Journal</i> , 2010, 31, 1898-1907.	1.0	218
26	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 728-737.	3.1	213
27	Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. <i>European Respiratory Journal</i> , 2014, 44, 1275-1288.	3.1	201
28	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 785-794.	5.2	201
29	Targeted therapies in pulmonary arterial hypertension. , 2014, 141, 172-191.		171
30	Pulmonary Arterial Hypertension: A Rare Complication of Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2014, 93, 160-166.	0.4	160
31	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 693-704.	1.6	155
32	HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. <i>Aids</i> , 2010, 24, 67-75.	1.0	149
33	Chemotherapy-Induced Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 356-371.	1.9	149
34	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013, 41, 1302-1307.	3.1	131
35	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 357-362.	0.3	126
36	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011, 8, 526-538.	6.1	125

#	ARTICLE	IF	CITATIONS
37	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 47, 1727-1736.	3.1	124
38	Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 125-134.	5.2	123
39	Potts Shunt in Children With Idiopathic Pulmonary Arterial Hypertension: Long-Term Results. <i>Annals of Thoracic Surgery</i> , 2012, 94, 817-824.	0.7	116
40	Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE study. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 948-955.	1.1	105
41	Mitomycin-Induced Pulmonary Venous Occlusive Disease. <i>Circulation</i> , 2015, 132, 834-847.	1.6	103
42	Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. <i>Advances in Therapy</i> , 2009, 26, 813-825.	1.3	96
43	Pulmonary veno-occlusive disease: Recent progress and current challenges. <i>Respiratory Medicine</i> , 2010, 104, S23-S32.	1.3	94
44	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 842-854.	2.5	94
45	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 96-103.	3.1	92
46	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 150-158.	0.3	91
47	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020, 56, 2001875.	3.1	90
48	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700217.	3.1	89
49	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 47, 541-552.	3.1	87
50	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. <i>European Respiratory Journal</i> , 2022, 59, 2102419.	3.1	83
51	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. <i>European Respiratory Journal</i> , 2012, 40, 630-640.	3.1	80
52	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014, 44, 1627-1634.	3.1	80
53	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2015, 46, 1721-1731.	3.1	80
54	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020, 73, 130-139.	1.8	78

#	ARTICLE	IF	CITATIONS
55	Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 49, 1-5.	0.8	77
56	Pulmonary hypertension associated with benfluorex exposure. <i>European Respiratory Journal</i> , 2012, 40, 1164-1172.	3.1	75
57	<i>BMPR2</i> mutation status influences bronchial vascular changes in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1668-1681.	3.1	68
58	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017, 65, 1683-1692.	3.6	68
59	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. <i>Chest</i> , 2018, 153, 143-151.	0.4	68
60	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. <i>Medicine (United States)</i> , 2011, 90, 201-211.	0.4	60
61	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	3.1	60
62	An Extreme Consequence of Splenectomy in Dehydrated Hereditary Stomatocytosis: Gradual Thromboembolic Pulmonary Hypertension and Lung Heart Transplantation. <i>Hemoglobin</i> , 2003, 27, 139-147.	0.4	59
63	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019, 28, 190023.	3.0	59
64	Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 833-842.	0.3	57
65	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016, 149, 353-361.	0.4	55
66	Ventilation/perfusion lung scan in pulmonary veno-occlusive disease. <i>European Respiratory Journal</i> , 2012, 40, 75-83.	3.1	53
67	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 647-655.	0.3	50
68	Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2</i> mutation. <i>European Respiratory Journal</i> , 2021, 58, 2004229.	3.1	50
69	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 170092.	3.0	48
70	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. <i>PLoS ONE</i> , 2018, 13, e0197112.	1.1	47
71	Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis. <i>Chest</i> , 2010, 137, 1297-1303.	0.4	46
72	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015, 94, e1800.	0.4	46

#	ARTICLE	IF	CITATIONS
73	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016, 48, 1517-1519.	3.1	44
74	Resting pulmonary artery pressure of 21â€“24â€“mmHg predicts abnormal exercise haemodynamics. <i>European Respiratory Journal</i> , 2016, 47, 1436-1444.	3.1	44
75	Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with <i>EIF2AK4</i> mutations. <i>European Respiratory Journal</i> , 2014, 44, 1069-1072.	3.1	43
76	Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 872-881.	0.4	43
77	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. <i>Lung</i> , 2018, 196, 157-164.	1.4	42
78	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. <i>European Respiratory Journal</i> , 2021, 58, 2100116.	3.1	41
79	Phenotype and outcome of pulmonary arterial hypertension patients carrying a <i>TBX4</i> mutation. <i>European Respiratory Journal</i> , 2020, 55, 1902340.	3.1	40
80	Birth Control and Pregnancy Management in Pulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 681-688.	0.8	39
81	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pULmonary arterial hypeRtEnsiOn. <i>International Journal of Cardiology</i> , 2016, 202, 52-58.	0.8	37
82	Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 303-316.	0.7	37
83	Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1234-1242.	0.3	37
84	Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension. <i>Drug Safety</i> , 2016, 39, 287-294.	1.4	35
85	Review: Therapeutic advances in pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 249-265.	1.0	33
86	Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2. <i>Chest</i> , 2015, 147, 1385-1394.	0.4	33
87	Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure. <i>European Respiratory Journal</i> , 2016, 48, 254-257.	3.1	31
88	Sex and gender in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2021, 30, 200330.	3.0	31
89	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017, 104, 404-411.	0.7	29
90	Factors predicting outcome after pulmonary endarterectomy. <i>PLoS ONE</i> , 2018, 13, e0198198.	1.1	29

#	ARTICLE	IF	CITATIONS
91	Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry. <i>International Journal of Cardiology</i> , 2014, 172, 561-567.	0.8	28
92	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020, 56, 2000279.	3.1	28
93	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	3.1	28
94	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 13-26.	1.0	27
95	Extracorporeal Life Support After Pulmonary Endarterectomy as a Bridge to Recovery or Transplantation: Lessons From 31 Consecutive Patients. <i>Annals of Thoracic Surgery</i> , 2016, 102, 260-268.	0.7	27
96	Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension. <i>Chest</i> , 2013, 144, 1512-1520.	0.4	26
97	Chronic thromboembolic pulmonary hypertension. <i>Presse Medicale</i> , 2015, 44, e409-e416.	0.8	26
98	Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?. <i>Presse Medicale</i> , 2011, 40, e87-e100.	0.8	25
99	A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. <i>Journal of Cardiac Failure</i> , 2017, 23, 29-35.	0.7	25
100	Pulmonary hypertension associated with neurofibromatosis type 1. <i>European Respiratory Review</i> , 2018, 27, 180053.	3.0	25
101	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1802108.	3.1	24
102	Clinical Challenges in Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 622S-628S.	0.4	23
103	Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1585-1596.	0.9	23
104	Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction. <i>Respiration</i> , 2013, 85, 471-477.	1.2	20
105	New pharmacotherapy options for pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2113-2131.	0.9	20
106	Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1102-1110.	0.3	20
107	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , 2018, 95, 244-250.	1.2	17
108	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. <i>ERJ Open Research</i> , 2022, 8, 00479-2021.	1.1	16

#	ARTICLE	IF	CITATIONS
109	Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, S248-S254.	1.5	15
110	Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 386-398.	0.3	15
111	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , 2021, 159, 1197-1207.	0.4	14
112	EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1â€™. <i>European Respiratory Journal</i> , 2012, 39, 1549-1550.	3.1	13
113	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016, 150, 256-258.	0.4	12
114	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	2.5	12
115	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021, 57, 2002208.	3.1	12
116	Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1469-1476.	0.8	10
117	Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 647-656.	0.3	10
118	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 882-892.	0.4	10
119	Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. <i>Archivos De Bronconeumologia</i> , 2020, 56, 578-585.	0.4	10
120	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1306-1315.	1.5	8
121	The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2014, 8, 84-92.	1.0	7
122	A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica. <i>European Respiratory Review</i> , 2016, 25, 93-96.	3.0	7
123	Preoperative C-reactive protein predicts early postoperative outcomes after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1532-1542.e5.	0.4	7
124	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , 2021, 58, 2100466.	3.1	7
125	Pulmonary thromboendarterectomy: The Marie Lannelongue Hospital experience. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 143-150.	0.6	6
126	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1285-1293.	0.3	6

#	ARTICLE	IF	CITATIONS
127	Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease. <i>Circulation</i> , 2012, 125, 2045-2047.	1.6	5
128	Atypical Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Medicine</i> , 2015, 128, e47-e49.	0.6	5
129	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 790-794.	1.0	5
130	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2020, 125, e466-e468.	1.5	5
131	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". <i>Circulation</i> , 2016, 133, e592-3.	1.6	4
132	Are indexed values better for defining exercise pulmonary hypertension?. <i>European Respiratory Journal</i> , 2017, 50, 1700240.	3.1	4
133	Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1128-1138.	1.0	4
134	Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?. <i>Frontiers in Medicine</i> , 2022, 9, 851935.	1.2	4
135	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. <i>European Respiratory Review</i> , 2014, 23, 260-263.	3.0	3
136	Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". <i>Circulation</i> , 2015, 132, e154.	1.6	3
137	Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. <i>International Journal of Cardiology</i> , 2015, 184, 763-765.	0.8	3
138	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021, 57, 2003132.	3.1	3
139	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	2.0	3
140	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021, 21, 3388-3400.	2.6	3
141	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	3
142	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. <i>Pulmonary Circulation</i> , 2022, 12, e12023.	0.8	2
143	Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e90-e91.	2.5	1
144	Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 524-525.	2.5	1

#	ARTICLE	IF	CITATIONS
145	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
146	Right heart failure. , 0, , 32-47.		0